Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Jan
01
Today In Oncology
Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo